Core One Labs’ Akome reaches research milestone with positive results from neurogenesis stimulation studies
Open the door to expanded patent coverage
VANCOUVER, BC / ACCESSWIRE / August 18, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (there “Company” Where “core one“), following its March 4, 2022 press release, is delighted to announce its wholly owned subsidiary, Akome Biotech Ltd. (“Akome“), the company’s biopharmaceutical research and development division, focused on the discovery and development of new psychedelic drugs targeting neurological and mental disorders, has achieved outstanding results through its studies of stimulation of neurogenesis (“neurogenesis studies“) relating to the effectiveness of its specific plant bioactives (“bioactive compounds) which are part of their patent-pending psychedelic drug formulations.
Neurogenesis studies, carried out by the Complutense University of Madrid (“Universidad Complutense”) and directed by Dr. Jose A. Morales-Garcia, are progressing very well and giving encouraging results. Dr. Morales-Garcia is Assistant Professor and Honorary Member of the Department of Cell Biology of the Faculty of Medicine of the Complutense University of Madrid, Scientist at the Center for Networked Biomedical Research in Neurodegenerative Diseases, as well as Professor of the Master in Pharmacology Research at the Autonomous University of Madrid.
Neurogenesis studies have revealed that the bioactive compounds selected by Akome are indeed viable candidate compounds that induce remarkable neurogenetic activity in controlled assays. The results of the study also show that each of the bioactive compounds have significant potential to elicit therapeutic activity against various neurological conditions and therefore could have therapeutic effects in more than one targeted disease.
These implications are of enormous significance, as they have the potential to expand the scope of Akome’s initial patent applications. As currently filed, Akome’s four (4) patent applications are very specific in scope, each covering only a single specific bioactive, associated with a specific psychedelic compound and targeting only a specific neurological condition. . The results of the neurogenesis study, however, strongly support that any of the bioactive compounds could be individually associated with any of the psychedelic compounds, and further that all combinations of the bioactive and psychedelic compounds could be beneficial in targeting the full spectrum of targeted diseases. , under investigation.
The next steps, which are already underway, are for Universidad Complutense to test all of Akome’s bioactive compounds in combination with psychedelic compounds, using the neurogenesis model, while designing animal studies in parallel.[i] to demonstrate beneficial effects in animal models of disease, starting with PD and AD.
“These groundbreaking results are extremely important to Core One Labs. Not only have our research studies confirmed that the four bioactive compounds specifically chosen for our drug formulations have the desired effect of inducing neurogenic activity, but the results also provide the Company with a significant opportunity to extend the scope of our patents. due to the fact that each bioactive can be used with different psychedelic compounds to elicit a different response”, said Joel Shacker, CEO of the company.
About Core One Labs Inc.
Core One Labs is a life science biotechnology research and development company focused on bringing psychedelic drugs to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the integration new technologies of administration systems.
The company has a multi-faceted business approach and integrates multiple business lines and complementary units to establish itself as an industry leader in the emerging and rapidly growing psychedelics market.
Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection for a proprietary psilocybin production system using engineered bacteria. It also holds 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental disorders, under its wholly owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other wholly owned subsidiary , Awakened Biosciences. Inc., for additional synthetic technologies for psilocybin and psilocin production methods.
In addition to the development of psychedelics and psychedelic compounds, Core One has interests in four medical clinics that maintain a combined database of over 275,000 patients. Through its clinics, the Company intends to integrate a deployment of its intellectual property related to psychedelic technologies and to participate in the advancement of psychedelic-based treatments for mental health disorders.
Core One Labs Inc.
Chief executive officer
FOR MORE INFORMATION PLEASE CONTACT:
The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the content of this press release.
The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. These factors include, among others: the risks and uncertainties associated with the Company’s limited operating history and the need to comply with stringent regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. Although Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate the legalization of psychedelics for recreational use. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.
[i] Animal studies are designed to show whether the drug works the same way inside the body as it does in the artificial lab environment. Additionally, testing on humans and animals is required by law before a drug can be approved.
THE SOURCE: Core One Labs Inc.
See the source version on accesswire.com: